GOSPEL 2-Colchicine for the treatment of gout flares in France - a GOSPEL survey subgroup analysis. Doses used in common practices regardless of renal impairment and age

Objectives: The objective of this sub-study was to assess the use of colchicine for the treatment of gout flares in real life conditions in the GOSPEL cohort following the 2006 EULAR recommendations for gout management. Methods: This national cross-sectional epidemiologic survey included outpatients with gout suffering from acute flare followed by randomly selected primary care physicians (n=398) and private practice rheumatologists (n=109) between October 2008 and September 2009 in France. Data regarding patient characteristics and treatment prescription was collected by each physician. Glomerular filtration rate (eGFR) was estimated using the Cockroft-Gault formula. Patients included in the survey for a gout flare filled in a specific self-questionnaire including colchicine effective intake and pain relief (numeric scale). Results: This analysis focused on the 349 patients presenting with gout flare and treated with colchicine. Mean (+/- SD) prescribed dose of colchicine was 2.8 (+/- 0.7) mg within the first 24 hours and the cumulative dose over the first three days of treatment was 6.9 (+/- 1.8) mg. Patients with mild decline in eGFR (eDFG 60-80 mL/min) were prescribed an average initial dose of 2.8 mg (perpendicular to 0.8) mg (n=58), 2.7 (perpendicular to 0.8) mg in chronic kidney disease (CKD) stage 3 (n=43) and 2.5 (+/- 0.7) mg in CKD stage 4 (n=2). Cumulative doses of colchicine did not take into account either renal impairment or age. Conclusions: This study draws attention to some misuse of colchicine in daily practice and the prescription of excessive doses especially in case of renal impairment. eGFR should be enforced in daily practice. (C) 2016 Societe francaise de rhumatologie. Published by Elsevier Masson SAS. All rights reserved.